Literature DB >> 8588222

Pharmacokinetics and therapeutic drug monitoring of immunosuppressants.

A Lindholm1, J Säwe.   

Abstract

Immunosuppressive drug treatment has developed considerably in recent years with new methods describing pharmacokinetic-pharmacodynamic relationships. Using in vitro models it is possible to predict the success of clinical immunosuppressive drug combinations. Furthermore, with the advances of analytical methodology it is now possible to measure minute amounts of potent immunosuppressants and to adjust dosing based on concentration measurements. Concentration control, which first was required for cyclosporine A, is being investigated for most immunosuppressive drugs in development. Characterisation of individual drug pharmacokinetics form the basis for successful immunosuppression. Among possible therapeutic drug monitoring methodologies, trough level monitoring is currently the method of choice.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8588222     DOI: 10.1097/00007691-199512000-00004

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  8 in total

1.  Population pharmacokinetic study of cyclosporine in Chinese renal transplant recipients.

Authors:  Bing Chen; WeiXia Zhang; ZhiDong Gu; Juan Li; YuXin Zhang; WeiMin Cai
Journal:  Eur J Clin Pharmacol       Date:  2010-12-16       Impact factor: 2.953

Review 2.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 3.  Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.

Authors:  G Zaza; S Granata; F Sallustio; G Grandaliano; F P Schena
Journal:  Clin Exp Immunol       Date:  2009-11-24       Impact factor: 4.330

4.  A comparison of the pharmacokinetics of tacrolimus and microemulsified cyclosporin in paediatric renal transplant recipients.

Authors:  Kenneth W Renton; John F S Crocker; Heather McLellan; Philip D Acott
Journal:  Eur J Clin Pharmacol       Date:  2004-07-01       Impact factor: 2.953

Review 5.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

6.  Management and clinical outcome of penetrating keratoplasty for long-term corneal changes in sympathetic ophthalmia.

Authors:  Saraswathi Ramamurthi; Ebube E Obi; Gordon N Dutton; Kanna Ramaesh
Journal:  J Ophthalmol       Date:  2011-05-05       Impact factor: 1.909

Review 7.  Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Alessandra Dalla Gassa; Antonio Lupo
Journal:  Int J Mol Sci       Date:  2015-02-17       Impact factor: 5.923

8.  Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation.

Authors:  Chetan Naik; Cody Moore; Matthew Pipeling; Jonathan D'Cunha; Kristine Ruppert; Christopher Ensor; Matthew Morrell
Journal:  Transplant Direct       Date:  2018-04-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.